Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: Immunogenicity and safety in 15-25 years old healthy Korean women

Journal of Gynecologic Oncology

Volumn 22, Issue 2, 2011, Pages 67-75

  Kim, Seung Cheol ^a   Song, Yong Sang ^b   Kim, Young Tae ^c   Kim, Young Tak ^d   Ryu, Ki Sung ^e   Gunapalaiah, Bhavyashree ^f   Bi, Dan ^f   Bock, Hans L ^f   Park, Jong Sup ^e  

^a Ewha Womans University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

AS04 adjuvanted; Cervical cancer; Geometric mean titres; Human papillomavirus 16 18; Immunogenicity; Seroconversion

Indexed keywords

CANCER VACCINE; HUMAN PAPILLOMAVIRUS 16 18 AS04 ADJUVANTED CERVICAL CANCER VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE;

ANTIBODY TITER; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; KOREA; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; MYALGIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEROCONVERSION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UTERINE CERVIX CANCER; VACCINATION; VOMITING;

EID: 80051971653     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2011.22.2.67     Document Type: Article

References (34)

1. American Cancer Society. Global cancer facts and figures. Atlanta: American Cancer Society; 2007.
2. Kim YT. Current status of cervical cancer and HPV infection in Korea. J Gynecol Oncol 2009;20:1-7.
3. Lee MY, Cho CH, Kwon SH, Song DK, Chung SW, Kang HO, et al. Annual report of gynecologic cancer registry program in Korean for 2002 (Jan. 1st, 2002 - Dec. 31st, 2002). Korean J Obstet Gynecol 2004;47:1029-70.
4. Shin HR, Park S, Hwang SY, Kim JE, Jung KW, Won YJ, et al. Trends in cervical cancer mortality in Korea 1993-2002: corrected mortality using national death certification data and national cancer incidence data. Int J Cancer 2008;122:393-7.
5. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, editors. Cancer incidence in five continents. IARC Scientific Publications No. 160. Lyon: IARC; 2007.
6. Bosch FX, de Sanjose S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007;23:213-27.
7. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
8. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
9. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32.
10. Bae JH, Lee SJ, Kim CJ, Hur SY, Park YG, Lee WC, et al. Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis. J Microbiol Biotechnol 2008;18:788-94.
11. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009;84:118-31.
12. WHO grants prequalification to Cervarix: GSK's vaccine to help combat cervical cancer in developing nations [Internet]. Middlessex: GlaxoSmithKline plc.; c2001-2011 [cited 2011 Jun 14]. Available from: http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10072.htm.
13. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009;374:301-14.
14. Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008;26:6630-8.
15. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, et al. Safety of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009;5:332-40.
16. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
17. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007;40:564-71.
18. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs 2008;68:359-72.
19. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine: analysis of a randomized placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85.
20. Stanley M. HPV vaccines: where are we now? J Fam Plann Reprod Health Care 2007;33:227-9.
21. Cervarix, GSK's cervical cancer vaccine, wins tender for Dutch national immunisation programme [Internet]. Middlessex: GlaxoSmithKline plc.; c2001-2011 [cited 2011 Jun 14]. Available from: http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10123.htm.
22. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008;4:425-34.
23. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
24. Freeman HP, Wingrove BK. Excess cervical cancer mortality: a marker for low access to health care in poor communities. Rockville, MD: National Cancer Institute; 2005.
25. Han CH, Cho HJ, Lee SJ, Bae JH, Bae SN, Namkoong SE, et al. The increasing frequency of cervical cancer in Korean women under 35. Cancer Res Treat 2008;40:1-5.
26. Medina DM, Valencia A, de Velasquez A, Huang LM, Prymula R, Garcia-Sicilia J, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health 2010; 46:414-21.
27. Kim YJ, Kim KT, Kim JH, Cha SD, Kim JW, Bae DS, et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04- adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. J Korean Med Sci 2010;25:1197-204.
28. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-9.
29. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937-49.
30. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;5:705-19.
31. Oh JK, Ju YH, Franceschi S, Quint W, Shin HR. Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study. BMC Infect Dis 2008;8:13.
32. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004;190:468-76.
33. Jun JK, Choi KS, Jung KW, Lee HY, Gapstur SM, Park EC, et al. Effectiveness of an organized cervical cancer screening program in Korea: results from a cohort study. Int J Cancer 2009;124:188-93.
34. Jang SN, Cho SI, Hwang SS, Jung-Choi K, Im SY, Lee JA, et al. Trend of socioeconomic inequality in participation in cervical cancer screening among Korean women. J Prev Med Public Health 2007;40:505-11.